Nain Biotech will present preclinical research data for a small molecule PDIA6/IRE1 modulator at the AACR Annual Meeting 2025

Nain Biotech will present preclinical research data for a small molecule PDIA6/IRE1 modulator at the AACR Annual Meeting 2025

Hangzhou, China, February 13, 2025 -- Nain Biotech, a global first-in-class drug discovery company focusing on cancer drug resistance, today announced that it will present a poster about preclinical research results of its first-in-class small molecule PDIA6/IRE1 modulator at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Details of the poster presentation are as follows:

Poster Title: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death

Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Session Start: 4/28/2025 2:00:00 PM
Session End: 4/28/2025 5:00:00 PM
Location: Poster Section 21
Poster Board Number: 14
Published Abstract Number: 3045

The AACR Annual Meeting 2025 will be held from April 25 to 30, 2025, in Chicago, USA. As one of the oldest and largest academic conferences on cancer research globally, the AACR Annual Meeting brings together the most cutting-edge research findings in the field of oncology. The inclusion of the company's research project in the AACR signifies recognition of the company's innovative capabilities and the clinical potential of its products.

About Nain Biotech

Nain Biotech was founded in December 2020. Nain focuses on developing novel CSC and RCD modulators, finding novel drug targets, and tackling drug resistance in cancer. Nain's team of scientists, by targeting drug resistance for cancer eradication, are hoping to bring significant clinical benefits to patients and committed to addressing unmet clinical needs.